NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

Detailed price information for Theravance Bio Ord (TBPH-Q) from The Globe and Mail including charting and trades.

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...

The corticosteroids market is driven by rising chronic diseases like asthma and COPD and innovations in drug delivery systems, enhancing treatment adherence. However, prolonged usage safety concerns ...

Showcase your company news with guaranteed exposure both in print and online Get ready for the annual Columbus Business First Power Breakfast… Where Ambition Finds Direction Join us as we continue our ...